pyridoxal phosphate has been researched along with Myocardial Ischemia in 12 studies
Pyridoxal Phosphate: This is the active form of VITAMIN B 6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is transiently converted into pyridoxamine phosphate (PYRIDOXAMINE).
pyridoxal 5'-phosphate : The monophosphate ester obtained by condensation of phosphoric acid with the primary hydroxy group of pyridoxal.
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous studies used manganese N,N'-bis-(pyridoxal 5-phosphate)ethylenediamine-N,N'-diacetic acid (MnDPDP) to detect myocardial ischemia at a dose of 0." | 3.70 | Detection of acute myocardial ischemia using first-pass dynamics of MnDPDP on inversion recovery echoplanar imaging. ( Arheden, H; Bremerich, J; Geschwind, JF; Higgins, CB; Saeed, M; Wendland, MF; Wyttenbach, R, 1999) |
| "Hydrogen sulfide (H( 2)S) is a biological mediator produced by enzyme-regulated pathways from L-cysteine, which is a substrate for cystathionine-gamma-lyase (CSE)." | 1.36 | L-cysteine stimulates hydrogen sulfide synthesis in myocardium associated with attenuation of ischemia-reperfusion injury. ( Baxter, GF; Elsey, DJ; Fowkes, RC, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (33.33) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elsey, DJ | 1 |
| Fowkes, RC | 1 |
| Baxter, GF | 1 |
| Fu, LW | 1 |
| Longhurst, JC | 1 |
| Dhalla, NS | 1 |
| Takeda, S | 1 |
| Elimban, V | 1 |
| Sesti, C | 1 |
| Koyama, M | 1 |
| Broekman, MJ | 1 |
| Marcus, AJ | 1 |
| Levi, R | 1 |
| Kandzari, DE | 2 |
| Labinaz, M | 1 |
| Cantor, WJ | 1 |
| Madan, M | 1 |
| Gallup, DS | 1 |
| Hasselblad, V | 1 |
| Joseph, D | 1 |
| Allen, A | 1 |
| Green, C | 1 |
| Hidinger, KG | 1 |
| Krucoff, MW | 1 |
| Christenson, RH | 1 |
| Harrington, RA | 1 |
| Tcheng, JE | 1 |
| Carrier, M | 1 |
| Emery, R | 1 |
| Harrington, R | 1 |
| Guertin, MC | 1 |
| Tardif, JC | 1 |
| Karlsson, JO | 3 |
| Mortensen, E | 1 |
| Pedersen, HK | 1 |
| Sager, G | 1 |
| Refsum, H | 2 |
| Wyttenbach, R | 1 |
| Saeed, M | 2 |
| Wendland, MF | 2 |
| Geschwind, JF | 1 |
| Bremerich, J | 1 |
| Arheden, H | 1 |
| Higgins, CB | 2 |
| Brurok, H | 2 |
| Skoglund, T | 1 |
| Berg, K | 1 |
| Skarra, S | 1 |
| Jynge, P | 2 |
| Lund, G | 1 |
| Smith, HJ | 1 |
| Eriksen, M | 1 |
| Towart, R | 1 |
| Toft, KG | 1 |
| Moen, O | 1 |
| Engebretsen, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| MEND-CABG II: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG Surgery[NCT00402506] | Phase 3 | 3,000 participants (Anticipated) | Interventional | 2006-11-30 | Completed | ||
| A Local Feasibility Study on Mangafodipir as an Adjunct to FOLFOX6 Chemotherapy in Patients Operated Upon Colon Cancer Stage Dukes' C[NCT00671996] | Phase 2 | 14 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for pyridoxal phosphate and Myocardial Ischemia
| Article | Year |
|---|---|
Mechanisms of the beneficial effects of vitamin B6 and pyridoxal 5-phosphate on cardiac performance in ischemic heart disease.
Topics: Animals; Cardiotonic Agents; Heart; Myocardial Ischemia; Pyridoxal Phosphate; Reperfusion Injury; Vi | 2013 |
Contrast-enhanced MRI for quantification of myocardial viability.
Topics: Animals; Contrast Media; Dysprosium; Edetic Acid; Gadolinium DTPA; Humans; Magnetic Resonance Imagin | 1999 |
1 trial available for pyridoxal phosphate and Myocardial Ischemia
| Article | Year |
|---|---|
Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial).
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiotonic Agents; Coronary Angiography; Coronary Disease; Do | 2003 |
9 other studies available for pyridoxal phosphate and Myocardial Ischemia
| Article | Year |
|---|---|
L-cysteine stimulates hydrogen sulfide synthesis in myocardium associated with attenuation of ischemia-reperfusion injury.
Topics: Alkynes; Analysis of Variance; Animals; Cysteine; Disease Models, Animal; Drug Therapy, Combination; | 2010 |
A new function for ATP: activating cardiac sympathetic afferents during myocardial ischemia.
Topics: Action Potentials; Adenosine Diphosphate; Adenosine Triphosphate; Adrenergic Fibers; Animals; Cats; | 2010 |
Ectonucleotidase in sympathetic nerve endings modulates ATP and norepinephrine exocytosis in myocardial ischemia.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Animals; Exocytosis; Guinea Pigs; Male; Myocardia | 2003 |
Protective effect of pyridoxal-5-phosphate (MC-1) on perioperative myocardial infarction is independent of aortic cross clamp time: results from the MEND-CABG trial.
Topics: Adult; Aged; Aged, 80 and over; Aorta; Cardiovascular Diseases; Constriction; Coronary Artery Bypass | 2008 |
Cardiovascular effects of MnDPDP and MnCl2 in dogs with acute ischaemic heart failure.
Topics: Acute Disease; Animals; Cardiovascular System; Chlorides; Contrast Media; Depression, Chemical; Dise | 1997 |
Detection of acute myocardial ischemia using first-pass dynamics of MnDPDP on inversion recovery echoplanar imaging.
Topics: Animals; Contrast Media; Dose-Response Relationship, Drug; Echo-Planar Imaging; Edetic Acid; Female; | 1999 |
Myocardial manganese elevation and proton relaxivity enhancement with manganese dipyridoxyl diphosphate. Ex vivo assessments in normally perfused and ischemic guinea pig hearts.
Topics: Animals; Contrast Media; Coronary Circulation; Edetic Acid; Guinea Pigs; In Vitro Techniques; Magnet | 1999 |
Contrast-enhanced MR imaging in the diagnosis and preservation of cardiac viability.
Topics: Animals; Cardiotonic Agents; Contrast Media; Edetic Acid; Humans; Magnetic Resonance Imaging; Myocar | 2001 |
Cardioprotective effects of the MR contrast agent MnDPDP and its metabolite MnPLED upon reperfusion of the ischemic porcine myocardium.
Topics: Animals; Blood Pressure; Cardiotonic Agents; Contrast Media; Coronary Circulation; Disease Models, A | 2001 |